Moreover, the application of WES revealed that a high tumour mutational burden (TMB) may serve as a prognostic marker, predicting favourable overall survival in well-defined HER2-positive metastatic BC (MBC) patients undergoing conventional HER2-directed treatments and chemotherapy [45]. The gene discussed is ERBB2; the disease is neoplasm.